Danish Head and Neck Cancer Group   Report issue

Academic/Hospital Phase 3
Founded: Aarhus Denmark (1976)

Organization Overview

First Clinical Trial
2007
NCT00496652
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2019

Timeline

NOW
  • Now

Alternative names

Danish Head and Neck Cancer Group | Danish Head and Neck Cancer Group (DAHANCA)

Active Ingredients

Drugs in Phase 3 Trials (3)

cisplatin (platinol) (3 trials)

Nimorazole (nulogyl) (5 trials)

zalutumumab (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Carcinoma (Phase 3)

Carcinoma, Squamous Cell (Phase 3)

Head and Neck Neoplasms (Phase 3)

Hypoxia (Phase 3)

Laryngeal Diseases (Phase 2)

Neoplasms, Squamous Cell (Phase 3)

Squamous Cell Carcinoma of Head and Neck (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 6
  • # of Trial APIs: 3